Modulating the immune system as a therapeutic target for myelodysplastic syndromes and acute myeloid leukemia

被引：0

作者：

Putnam, Caroline M. ^{[1
]}

Kondeti, Lahari ^{[1
]}

Kesler, Meredith B. A. ^{[1
]}

Varney, Melinda E. ^{[1
]}

机构：

[1] Marshall Univ, Sch Pharm, Dept Pharmaceut Sci, Huntington, WV 25755 USA

来源：

BIOCHEMISTRY AND CELL BIOLOGY | 2023年

关键词：

myelodysplastic syndromes; acute myeloid leukemia; immunotherapy; NF-KAPPA-B; WT1 PEPTIDE VACCINATION; HEMATOPOIETIC STEM-CELLS; INNATE IMMUNE; INTERLEUKIN-6; LEVELS; NLRP3; INFLAMMASOME; PHASE-2; TRIAL; T-CELLS; AML; RESPONSES;

D O I：

10.1139/bcb-2022-0374

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Modulating the immune system to treat diseases, including myeloid malignancies, has resulted in the development of a multitude of novel therapeutics in recent years. Myelodysplastic syndromes or neoplasms (MDS) and acute myeloid leukemia (AML) are hematologic malignancies that arise from defects in hematopoietic stem and progenitor cells (HSPCs). Dysregulated immune responses, especially in innate immune and inflammatory pathways, are highly associated with the acquisition of HSPC defects in MDS and AML pathogenesis. In addition to utilizing the immune system in immunotherapeutic interventions such as chimeric antigen receptor T cell therapy, vaccines, and immune checkpoint inhibitors, mitigating dysregulation of innate immune and inflammatory responses in MDS and AML remains a priority in slowing the initiation and progression of these myeloid malignancies. This review provide a comprehensive summary of the current progress of diverse strategies to utilize or modulate the immune system in the treatment of MDS and AML.

引用

页码：481 / 495

页数：15

共 129 条

[1] Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes [J].

Abaza, Yasmin ;

Zeidan, Amer M. .

CELLS, 2022, 11 (14)

[2] Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia [J].

Agerstam, Helena ;

Karlsson, Christine ;

Hansen, Nils ;

Sanden, Carl ;

Askmyra, Maria ;

von Palffy, Sofia ;

Hogberg, Carl ;

Rissler, Marianne ;

Wunderlich, Mark ;

Juliusson, Gunnar ;

Richter, Johan ;

Sjostrom, Kjell ;

Bhatia, Ravi ;

Mulloy, James C. ;

Jaras, Marcus ;

Fioretos, Thoas .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (34) :10786-10791

[3] Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia [J].

Anguille, Sebastien ;

Van de Velde, Ann L. ;

Smits, Evelien L. ;

Van Tendeloo, Viggo F. ;

Juliusson, Gunnar ;

Cools, Nathalie ;

Nijs, Griet ;

Stein, Barbara ;

Lion, Eva ;

Van Driessche, Ann ;

Vandenbosch, Irma ;

Verlinden, Anke ;

Gadisseur, Alain P. ;

Schroyens, Wilfried A. ;

Muylle, Ludo ;

Vermeulen, Katrien ;

Maes, Marie-Berthe ;

Deiteren, Kathleen ;

Malfait, Ronald ;

Gostick, Emma ;

Lammens, Martin ;

Couttenye, Marie M. ;

Jorens, Philippe ;

Goossens, Herman ;

Price, David A. ;

Ladell, Kristin ;

Oka, Yoshihiro ;

Fujiki, Fumihiro ;

Oji, Yusuke ;

Sugiyama, Haruo ;

Berneman, Zwi N. .

BLOOD, 2017, 130 (15) :1713-1721

[4] A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 μci/Kg/Dose [J].

Atallah, Ehab L. ;

Orozco, Johnnie J. ;

Craig, Michael ;

Levy, Moshe Yair ;

Finn, Laura E. ;

Khan, Sharif S. ;

Perl, Alexander E. ;

Park, Jae H. ;

Roboz, Gail J. ;

Tse, William ;

Begna, Kebede H. ;

Mawad, Raya ;

Rizzieri, David A. ;

Berger, Mark S. ;

Jurcic, Joseph G. .

BLOOD, 2018, 132

[5]

Attar E.C., 2010, Blood, V116, P331

[6] Risk prediction in MDS: independent validation of the IPSS-M-ready for routine? [J].

Baer, Constance ;

Huber, Sandra ;

Hutter, Stephan ;

Meggendorfer, Manja ;

Nadarajah, Niroshan ;

Walter, Wencke ;

Platzbecker, Uwe ;

Goetze, Katharina S. ;

Kern, Wolfgang ;

Haferlach, Torsten ;

Hoermann, Gregor ;

Haferlach, Claudia .

LEUKEMIA, 2023, 37 (04) :938-941

[7] Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes [J].

Banerjee, Titas ;

Calvi, Laura M. ;

Becker, Michael W. ;

Liesveld, Jane L. .

BLOOD REVIEWS, 2019, 36 :57-69

[8] Chronic immune response dysregulation in MDS pathogenesis [J].

Barreyro, Laura ;

Chlon, Timothy M. ;

Starczynowski, Daniel T. .

BLOOD, 2018, 132 (15) :1553-1560

[9] OPINION Is NF-κB a good target for cancer therapy? Hopes and pitfalls [J].

Baud, Veronique ;

Karin, Michael .

NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (01) :33-40

[10] Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma [J].

Baumeister, Susanne H. ;

Murad, Joana ;

Werner, Lillian ;

Daley, Heather ;

Trebeden-Negre, Helene ;

Gicobi, Joanina K. ;

Schmucker, Adam ;

Reder, Jake ;

Sentman, Charles L. ;

Gilham, David E. ;

Lehmann, Frederic F. ;

Galinsky, Ilene ;

DiPietro, Heidi ;

Cummings, Kristen ;

Munshi, Nikhil C. ;

Stone, Richard M. ;

Neuberg, Donna S. ;

Soiffer, Robert ;

Dranoff, Glenn ;

Ritz, Jerome ;

Nikiforow, Sarah .

CANCER IMMUNOLOGY RESEARCH, 2019, 7 (01) :100-112

← 1 2 3 4 5 6 7 8 9 10 →